Cover Image
市場調查報告書

非小細胞肺癌:全球臨床實驗檢討

Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 229164
出版日期 內容資訊 英文 3400 Pages
訂單完成後即時交付
價格
Back to Top
非小細胞肺癌:全球臨床實驗檢討 Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016
出版日期: 2016年09月30日 內容資訊: 英文 3400 Pages
簡介

本報告提供非小細胞肺癌相關臨床研究之最新趨勢分析,以疾病概要為首,提供地區及主要國家的臨床實驗狀況,Phase別·進展狀況別臨床實驗資料,被實驗者的募集情況,有潛力的贊助商,以及彙整各企業·研究機關臨床實驗簡介等資訊,為您概述為以下內容。

目錄

簡介

  • 非小細胞肺癌
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數和平均實驗人數
    • 亞太地區的主要5個國家
    • 歐洲的主要5個國家
    • 北美的主要國家
    • 中東非洲的主要5個國家

在G7各國臨床實驗

在G7各國臨床實驗:Phase別

在G7各國臨床實驗:各進展狀況

在E7各國臨床實驗

在E7各國臨床實驗:Phase別

在E7各國臨床實驗:各進展狀況

Phase別臨床實驗

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗

一定期間所採用的實驗對象

贊助商的種類別臨床實驗

有潛力的贊助商

  • 參加非小細胞肺癌治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • AstraZeneca PLC
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • Novartis AG
    • Merck & Co., Inc
    • GlaxoSmithKline plc
    • C. H. Boehringer Sohn AG & Co. KG
  • 有代表性的醫院·研究機關臨床實驗概要
    • National Cancer Institute
    • The University of Texas M. D. Anderson Cancer Center
    • Memorial Sloan Kettering Cancer Center
    • West Japan Oncology Group
    • European Organization for Research and Treatment of Cancer
    • Radiation Therapy Oncology Group
    • Sun Yat-sen University
    • Eastern Cooperative Oncology Group
    • Sarah Cannon Research Institute
    • Barbara Ann Karmanos Cancer Institute

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3815CTIDB

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Latest Clinical Trials News on Non-Small Cell Lung Cancer 31
  • Oct 13, 2016: OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 31
  • Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 31
  • Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 32
  • Oct 09, 2016: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer 33
  • Oct 09, 2016: Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck's KEYTRUDA (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients 34
  • Oct 09, 2016: Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer 36
  • Oct 09, 2016: Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study 37
  • Oct 09, 2016: Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016 38
  • Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours 39
  • Oct 03, 2016: First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress 40
  • Oct 03, 2016: New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach 41
  • Sep 29, 2016: Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program 44
  • Sep 28, 2016: Two New Trials of Merck's KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 44
  • Sep 28, 2016: Merck to Present Phase II Program Updates on Tepotinib at ESMO 2016 45
  • Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress 46
  • Sep 26, 2016: Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 46
  • Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 47
  • Sep 25, 2016: New BGB324 study points to novel mechanism to enhance immunotherapy efficacy 48
  • Sep 23, 2016: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia in untreated adult ALK+ NSCLC patients 48
  • Sep 21, 2016: Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress 49
  • Sep 15, 2016: Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers 50
  • Sep 14, 2016: Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor 50
  • Sep 08, 2016: New analysis showed dose adjustment of Gilotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer 51
  • Aug 31, 2016: Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy 51
  • Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA 52
  • Aug 15, 2016: BeyondSpring Announces First Patient Enrolled in China in a Global Phase 3 Trial of Plinabulin for Non-Small Cell Lung Cancer 52
  • Aug 11, 2016: ValiSeek Clinical Development Update and Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia 53
  • Aug 10, 2016: Oncolytics Biotech Reports Additional Data from Randomized Phase II Study of REOLYSIN in Non-Small Cell Lung Cancer 53
  • Aug 09, 2016: Astrazeneca Update on Selumetinib Phase III Trial 54
  • Aug 09, 2016: Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo (nivolumab) in Treatment-Naive Patients with Advanced Non-Small Cell Lung Cancer 55
  • Aug 05, 2016: Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naive Patients with Advanced Non-Small Cell Lung Cancer 55
  • Jul 25, 2016: Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 56
  • Clinical Trial Profile Snapshots 57

Appendix 3397

  • Abbreviations 3397
  • Definitions 3397
  • Research Methodology 3398
  • Secondary Research 3398
  • About GlobalData 3399
  • Contact Us 3399
  • Disclaimer 3399
  • Source 3400

List of Tables

  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures

  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
  • Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
  • GlobalData Methodology 3398
Back to Top